

# Amanda Heslegrave

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5884611/amanda-heslegrave-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

69  
papers

1,749  
citations

26  
h-index

40  
g-index

85  
ext. papers

2,399  
ext. citations

7.3  
avg, IF

4.55  
L-index

#	Paper	IF	Citations
69	Assessing Neurofilaments as Biomarkers of Neuroprotection in Progressive Multiple Sclerosis: From the MS-STAT Randomized Controlled Trial.. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2022</b> , 9,	9.1	1
68	Plasma neurofilament light chain protein as a predictor of days in delirium and deep sedation, mortality and length of stay in critically ill patients.. <i>EBioMedicine</i> , <b>2022</b> , 80, 104043	8.8	0
67	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. <i>PLoS ONE</i> , <b>2022</b> , 17, e0267298	3.7	1
66	Neurofilament Light in CSF and Plasma Is a Marker of Neuronal Damage in HTLV-1-Associated Myelopathy and Correlates With Neuroinflammation. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2021</b> , 8,	9.1	2
65	Population-based blood screening for preclinical Alzheimer's disease in a British birth cohort at age 70. <i>Brain</i> , <b>2021</b> , 144, 434-449	11.2	21
64	Serum neurofilament light concentration does not increase following exposure to low velocity football heading.. <i>Science and Medicine in Football</i> , <b>2021</b> , 5, 188-194	2.7	0
63	A population-based study of head injury, cognitive function and pathological markers. <i>Annals of Clinical and Translational Neurology</i> , <b>2021</b> , 8, 842-856	5.3	1
62	Evidence of upregulation of the cholinergic anti-inflammatory pathway in late-life depression. <i>Journal of Affective Disorders</i> , <b>2021</b> , 286, 275-281	6.6	3
61	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. <i>Journal of Internal Medicine</i> , <b>2021</b> , 290, 583-601	10.8	15
60	Plasma Neurofilament Light as a Biomarker of Neurological Involvement in Wilson's Disease. <i>Movement Disorders</i> , <b>2021</b> , 36, 503-508	7	5
59	Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington's disease. <i>Scientific Reports</i> , <b>2021</b> , 11, 3481	4.9	3
58	Cerebrospinal fluid neurofilament light levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment.. <i>F1000Research</i> , <b>2021</b> , 10, 614	3.6	0
57	Cerebrospinal fluid metallomics in cerebral amyloid angiopathy: an exploratory analysis. <i>Journal of Neurology</i> , <b>2021</b> , 1	5.5	2
56	Axonal marker neurofilament light predicts long-term outcomes and progressive neurodegeneration after traumatic brain injury. <i>Science Translational Medicine</i> , <b>2021</b> , 13, eabg9922	17.5	9
55	Association of CSF sTREM2, a marker of microglia activation, with cholinergic basal forebrain volume in major depressive disorder. <i>Journal of Affective Disorders</i> , <b>2021</b> , 293, 429-434	6.6	1
54	Neurofilament light plasma concentration positively associates with age and negatively associates with weight and height in the dog. <i>Neuroscience Letters</i> , <b>2021</b> , 744, 135593	3.3	2
53	A multi-center study of neurofilament assay reliability and inter-laboratory variability. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , <b>2020</b> , 21, 452-458	3.6	8

52	Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome. <i>Journal of Neuroinflammation</i> , <b>2020</b> , 17, 86	10.1	23
51	Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2020</b> , 49, 56-76	2.6	7
50	Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 74, 1189-1201	4.3	19
49	Multicentre longitudinal study of fluid and neuroimaging BIOMarkers of AXonal injury after traumatic brain injury: the BIO-AX-TBI study protocol. <i>BMJ Open</i> , <b>2020</b> , 10, e042093	3	4
48	Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease. <i>Science Translational Medicine</i> , <b>2020</b> , 12,	17.5	24
47	Familial Alzheimer's disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta. <i>Molecular Psychiatry</i> , <b>2020</b> , 25, 2919-2931	15.1	51
46	In vivo detection of cerebral tau pathology in long-term survivors of traumatic brain injury. <i>Science Translational Medicine</i> , <b>2019</b> , 11,	17.5	34
45	The prognostic value of neurofilament levels in patients with sepsis-associated encephalopathy - A prospective, pilot observational study. <i>PLoS ONE</i> , <b>2019</b> , 14, e0211184	3.7	30
44	PDXK mutations cause polyneuropathy responsive to pyridoxal 5'-phosphate supplementation. <i>Annals of Neurology</i> , <b>2019</b> , 86, 225-240	9.4	18
43	Breaking the cycle: Reversal of flux in the tricarboxylic acid cycle by dimethyl fumarate. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2019</b> , 6, e562	9.1	7
42	Exercise as a potential modulator of inflammation in patients with Alzheimer's disease measured in cerebrospinal fluid and plasma. <i>Experimental Gerontology</i> , <b>2019</b> , 121, 91-98	4.5	34
41	Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2019</b> , 11, 19	9	47
40	Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X. <i>Human Molecular Genetics</i> , <b>2019</b> , 28, 3528-3542	5.6	14
39	The gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. <i>Science Translational Medicine</i> , <b>2019</b> , 11,	17.5	77
38	Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis. <i>Journal of the Peripheral Nervous System</i> , <b>2019</b> , 24, 314-319	4.7	28
37	Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. <i>Alzheimer's Research and Therapy</i> , <b>2019</b> , 11, 94	9	15
36	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. <i>NeuroImage: Clinical</i> , <b>2019</b> , 24, 102077	5.3	13
35	CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2019</b> , 6, e512	9.1	27

34	Plasma tau is increased in frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2018</b> , 89, 804-807	5.5	28
33	Sense and antisense RNA are not toxic in <i>Drosophila</i> models of C9orf72-associated ALS/FTD. <i>Acta Neuropathologica</i> , <b>2018</b> , 135, 445-457	14.3	45
32	Amyloid $\beta$ peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2018</b> , 10, 311-321	5.2	15
31	Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease. <i>Scientific Reports</i> , <b>2018</b> , 8, 4260	4.9	17
30	Cerebrospinal fluid tau, A $\beta$ and sTREM2 in Former National Football League Players: Modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 1159-1170	1.2	64
29	Stability of blood-based biomarkers of Alzheimer's disease over multiple freeze-thaw cycles. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2018</b> , 10, 448-451	5.2	35
28	Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 39	9	37
27	Molecular biomarkers of Alzheimer's disease: progress and prospects. <i>DMM Disease Models and Mechanisms</i> , <b>2018</b> , 11,	4.1	109
26	Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 79	9	31
25	Inflammatory markers of CHMP2B-mediated frontotemporal dementia. <i>Journal of Neuroimmunology</i> , <b>2018</b> , 324, 136-142	3.5	6
24	G-quadruplex-binding small molecules ameliorate FTD/ALS pathology and. <i>EMBO Molecular Medicine</i> , <b>2018</b> , 10, 22-31	12	119
23	P1-188: MODELLING AMYLOID BETA PROFILES IN IPSC-DERIVED CORTICAL NEURONS OF MULTIPLE FAMILIAL ALZHEIMER'S DISEASE GENOTYPES, INCLUDING A CASE STUDY OF SAME DONOR CULTURE MEDIA, CSF AND BRAIN TISSUE <b>2018</b> , 14, P350-P351		
22	O2-04-04: LONGITUDINAL MEASUREMENT OF SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER'S DISEASE <b>2018</b> , 14, P623-P624		
21	P1-026: CEREBROSPINAL FLUID TAU, A $\beta$ AND STREM2 IN FORMER NATIONAL FOOTBALL LEAGUE PLAYERS: MODELING THE RELATIONSHIP BETWEEN REPETITIVE HEAD IMPACTS, MICROGLIAL ACTIVATION, AND NEURODEGENERATION <b>2018</b> , 14, P275-P276		
20	O3-09-03: SERUM NEUROFILAMENT LIGHT LEVELS CORRELATE WITH SEVERITY MEASURES AND NEURODEGENERATION MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE <b>2018</b> , 14, P1037-P1037		
19	Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 113	9	38
18	Interlaboratory validation of cerebrospinal fluid $\beta$ synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2018</b> , 10, 461-470	5.2	5
17	Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	67

16	Blood Biomarkers for Alzheimer's Disease: Much Promise, Cautious Progress. <i>Molecular Diagnosis and Therapy</i> , <b>2017</b> , 21, 13-22	4.5	26
15	Combined tissue and fluid proteomics with Tandem Mass Tags to identify low-abundance protein biomarkers of disease in peripheral body fluid: An Alzheimer's Disease case study. <i>Rapid Communications in Mass Spectrometry</i> , <b>2017</b> , 31, 153-159	2.2	30
14	Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid- $\beta$ Concentration. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 56, 885-891	4.3	5
13	A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology. <i>Translational Psychiatry</i> , <b>2016</b> , 6, e952	8.6	33
12	Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , <b>2016</b> , 11, 3	19	168
11	Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 1587-1595	5	53
10	Genetic Variants and Related Biomarkers in Sporadic Alzheimer's Disease. <i>Current Genetic Medicine Reports</i> , <b>2015</b> , 3, 19-25	2.2	1
9	Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. <i>Molecular Neurodegeneration</i> , <b>2015</b> , 10, 64	19	87
8	P2-105: IDENTIFYING MARKERS OF MICROGLIA ACTIVATION IN CSF FROM PATIENTS WITH ALZHEIMER'S DISEASE USING A NOVEL MASS SPECTROMETRY APPROACH <b>2014</b> , 10, P509-P509		
7	Deletion of Lkb1 in pro-opiomelanocortin neurons impairs peripheral glucose homeostasis in mice. <i>Diabetes</i> , <b>2011</b> , 60, 735-45	0.9	41
6	Activation of AMP-activated protein kinase by vascular endothelial growth factor mediates endothelial angiogenesis independently of nitric-oxide synthase. <i>Journal of Biological Chemistry</i> , <b>2010</b> , 285, 10638-52	5.4	63
5	Congenital hyperinsulinism due to mutations in HNF4A and HADH. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2010</b> , 11, 185-91	10.5	19
4	Nitric oxide-dependent damage to neuronal mitochondria involves the NMDA receptor. <i>European Journal of Neuroscience</i> , <b>2002</b> , 15, 458-64	3.5	48
3	Haem oxygenase/nitric oxide synthase interaction: a role in neurodegeneration?. <i>Biochemical Society Transactions</i> , <b>2002</b> , 30, A84-A84	5.1	
2	Cerebrospinal fluid neurofilament light chain levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment. <i>F1000Research</i> , <b>2010</b> , 10, 614	3.6	2
1	Longitudinal dynamics of mutant huntingtin and neurofilament light in Huntington's disease: the prospective HD-CSF study		2